Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Febuxostat is a non-purine, selective inhibitor of xanthine oxidase being developed for the management of hyperuricaemia in patients with gout. With febuxostat 10-120 mg, the pharmacokinetics are linear. No dose adjustment appears to be necessary in those with renal insufficiency or mild-to-moderate hepatic impairment. Febuxostat 10-120 mg/day rapidly and sustainably reduces serum uric acid by 25-70% in uric acid underexcretors and overproducers. Prophylaxis with colchicine or a non-steroidal anti-inflammatory drug can mitigate the gout-flare risk from the rapid urate lowering after febuxostat initiation. Febuxostat is well tolerated, the majority of treatment-related adverse events are transient and mild-to-moderate in severity. Febuxostat can broaden the therapeutic options for urate-lowering therapy in those with gout.
Schumacher
H Ralph
HR
University of Pennsylvania, VA Medical Center, Philadelphia, Pennsylvania, USA. schumacr@mail.med.upenn.edu
D019468:Disease Management; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000069465:Febuxostat; D006073:Gout / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000201:enzymology; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors* / Q000502:physiology
D004791:Enzyme Inhibitors; D013844:Thiazoles; D000069465:Febuxostat; D014969:Xanthine Oxidase